DMTRF (3-D Matrix) ROCE %: 53.64% (As of Jan. 2026)

What is 3-D Matrix ROCE %?

3-D Matrix DMTRF 55 ROCE % is 53.64% as of Jan. 2026. GuruFocus rates DMTRF with a GF Score™ of 55/100 and a GF Value™ of $2.15 (Fairly Valued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. 3-D Matrix's annualized ROCE % for the quarter that ended in Jan. 2026 was 53.64%.

3-D Matrix (OTCPK:DMTRF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

3-D Matrix ROCE % Related Terms

3-D Matrix ROCE % Historical Data

* Premium members only.

The historical data trend for 3-D Matrix's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3-D Matrix ROCE % Chart

3-D Matrix Annual Data

Trend

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Apr25

Apr26

ROCE %

Get a 7-Day Free Trial

-47.74

-50.00

1.24

-53.39

67.88

3-D Matrix Quarterly Data
	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25	Apr25	Jul25	Oct25	Jan26	Apr26
ROCE %	Get a 7-Day Free Trial															-85.51	75.60	85.12	53.64	93.19

55GF Score

3-D Matrix Ltd DMTRF

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

3-D Matrix ROCE % Calculation

3-D Matrix's annualized ROCE % for the fiscal year that ended in Apr. 2026 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Apr. 2026 )		(A: Apr. 2025 )		(A: Apr. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Apr. 2026 )		(A: Apr. 2025 )		(A: Apr. 2026 )
	=	26.209	/	( ( (45.19 - 10.955)	+	(61.563 - 18.578) )	/ 2 )
	=	26.209	/	( (34.235	+	42.985)	/ 2 )
	=	26.209	/	38.61
	=	67.88 %

3-D Matrix's ROCE % of for the quarter that ended in Jan. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2026 )		(Q: Oct. 2025 )		(Q: Jan. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2026 )		(Q: Oct. 2025 )		(Q: Jan. 2026 )
	=	18.508	/	( ( (44.922 - 11.09)	+	(48.347 - 13.175) )	/ 2 )
	=	18.508	/	( ( 33.832	+	35.172 )	/ 2 )
	=	18.508	/	34.502
	=	53.64 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 53.64% mean?

3-D Matrix (DMTRF) has a ROCE % of 53.64% as of Jan. 2026.

Is 3-D Matrix's ROCE % too high?

3-D Matrix's current ROCE % is 53.64%. The Medical Devices & Instruments industry median ROCE % is 2.23. 3-D Matrix's value of 53.64% is 2305.4% above this industry median. Overall, 3-D Matrix has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does 3-D Matrix's ROCE % compare to ABT and SYK?

3-D Matrix's ROCE % of 53.64% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. 3-D Matrix's value of 53.64% is 2305.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3-D Matrix's current ROCE % of 53.64% is 2305.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3-D Matrix's current ROCE % is 53.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is 3-D Matrix stock overvalued right now?

Based on GuruFocus' analysis, 3-D Matrix (DMTRF) is currently considered Fairly Valued. The stock's GF Value™ is $2.15, compared to a current price of $2.25 — trading 4.7% above its estimated fair value. The current ROCE % is 53.64% and 2305.4% above the Medical Devices & Instruments industry median of 2.23. 3-D Matrix's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For 3-D Matrix (DMTRF), the current ROCE % is 53.64% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3-D Matrix (DMTRF) Overvalued in 2026?

Based on GuruFocus' analysis, 3-D Matrix stock appears to be overvalued. The current stock price of $2.25 is trading 4.7% above its estimated GF Value™ of $2.15. GuruFocus considers 3-D Matrix to be Fairly Valued.

Key valuation signals for DMTRF:

ROCE %: 53.64%
GF Value™: $2.15 vs. price of $2.25 (4.7% above fair value)
GF Score™: 55/100 with 3 warning signs
Industry Position: 2305.4% above the Medical Devices & Instruments median

No single metric tells the full story. See the DMTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

3-D Matrix Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies TSE:7779 TSE:6823 TSE:4548 TSE:7600 TSE:4889 TSE:6678 TSE:7792 TSE:3079 TSE:7575 TSE:9341 ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges 7777:Japan

Address 3-2-4 Kojimachi, Chiyoda-ku, 7th floor, Kojimachi HF Building, Tokyo, JPN, 102-0083

Website http://www.3d-matrix.co.jp

3-D Matrix Ltd is engaged in the research, development, manufacture, and sale of medical devices based on the self-assembling peptide technology. Its products include PuraMatrix, High Concentration PuraMatrix, Modified Peptide and GMP Grade PuraMatrix.

55GF Score

Get the complete analysis for DMTRF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.25

Price

$2.15

GF Value

View DMTRF Analysis

See ROCE % data for all stocks →